Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C(max) and improved tolerability, in patients with solid tumors

5-fluorouracil (5-FU) and 5-FU derivatives, such as capecitabine, UFT, and S-1, are the mainstay of chemotherapy treatment for gastrointestinal cancers, and other solid tumors. Compared with other cytotoxic chemotherapies, these drugs generally have a favorable safety profile, but hematologic and ga...

Descripción completa

Detalles Bibliográficos
Autores principales: Ajani, Jaffer A., Javle, Milind, Eng, Cathy, Fogelman, David, Smith, Jackie, Anderson, Barry, Zhang, Chun, Iizuka, Kenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575509/
https://www.ncbi.nlm.nih.gov/pubmed/32377978
http://dx.doi.org/10.1007/s10637-020-00939-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575509/
https://www.ncbi.nlm.nih.gov/pubmed/32377978
http://dx.doi.org/10.1007/s10637-020-00939-w

Ejemplares similares